VIRX Viracta Therapeutics, Inc.

Overview and Growth

Viracta Therapeutics, Inc. recorded fiscal 2023 net loss of $51.06M. Diluted earnings per share were -$1.32, translating the period’s attributable earnings into the amount reported for each diluted share. The diluted weighted-average share count was 38.62M, linking total earnings with the per-share result received by shareholders. Diluted shares moved 2.2% from 37.79M in fiscal 2022, leaving the current share base higher year over year. The company employed $56.69M of total assets, the balance-sheet base supporting its current operating and cash-flow results.

Profitability

Operations produced a $50.69M operating loss before non-operating and tax effects. The company ended the period with a net loss of $51.06M, extending the operating result through all remaining items. The company reported negative EBITDA of $50.20M, adding a pre-interest, tax, depreciation, and amortization view of the operating shortfall. Income tax expense totaled $0.00, providing the reported tax component that separates pretax and after-tax earnings. The net loss equaled 278.7% of period-end equity, showing the deficit relative to book capital. The net loss equaled 90.1% of period-end assets, showing the deficit relative to the asset base. The bottom-line deficit increased from $49.20M in fiscal 2022 to $51.06M.

Liquidity and Capital Structure

Total assets were $56.69M, supported by $38.37M of liabilities and $18.32M of shareholder equity. At period end, current assets of $54.96M compared with current liabilities of $38.37M, defining the company’s short-term resource position. Current assets covered current liabilities by 1.43x, leaving a positive buffer for near-term obligations. Reported cash and equivalents were $12.32M, separating immediately recognizable cash resources from the rest of the current-asset base. Cash and equivalents represented 32.1% of current liabilities, showing the portion of near-term obligations matched by reported cash alone. The company carried $25.27M of total debt at period end, which frames its leverage and debt-service burden. Against book equity, debt measured 1.38x, placing the company’s financial leverage in clear balance-sheet terms. Debt represented 44.6% of total assets, placing borrowing in the context of the company’s full resource base. Book equity represented 32.3% of total assets, quantifying the balance-sheet share supported by shareholder capital. The liabilities-to-assets relationship was 67.7%, placing reported obligations against the full positive asset balance. Measured against total assets, cash and equivalents represented 21.7%, a balance-sheet composition measure rather than a liquidity forecast. The asset base changed 40.9% from $95.99M in fiscal 2022, leaving current total assets lower year over year. Book equity was 70.0% lower than fiscal 2022 equity of $61.10M, showing how shareholder capital changed year over year. Compared with $36.77M in fiscal 2022, the current cash balance moved 66.5% and finished lower.

Cash Flow and Earnings Quality

The company reported an operating cash outflow of $39.89M, rather than cash generation from operations. The company spent $138.00K on capital expenditures while operations also absorbed cash, so both ongoing activity and investment drew on liquidity during the period. The company recorded a $40.03M cash deficit after capital spending for the period. The cash deficit after capital spending represented 70.6% of the period-end asset base. Compared with a $35.46M operating cash outflow in fiscal 2022, the current outflow increased to $39.89M.

Based on the annual report for the fiscal year ending Dec 31, 2023. Analysis generated Sep 24, 2026.